Surge Therapeutics, a Cambridge, MA-based biotechnology company, raised $26M in Series A funding.
The round was led by Camford Capital, with participation from Khosla Ventures, Intuitive Ventures, Pitango HealthTech, 8VC, Alumni Ventures, and the Cancer Research Institute.
The company intends to use the funds to accelerate development of its intraoperative immunotherapy approach, expand the team, and initiate clinical trials for its injectable biodegradable hydrogel.
Led by CEO and Founder Dr. Michael Goldberg, Surge Therapeutics is a company developing an injectable biodegradable hydrogel that enables extended, localized release of cancer immunotherapy at the site of surgical tumor resection to improve patient survival outcomes.
Built upon research conducted in founder and CEO Dr. Michael Goldberg’s laboratory at Harvard Medical School, the SURGE Therapeutics™ injectable biodegradable hydrogel enables extended, localized release of cancer immunotherapy at the site of surgical tumor resection. In multiple aggressive murine models of metastasizing cancer, intraoperative immunotherapy vastly improved survival benefit relative to traditional routes of administration, whether systemic or local. Dr. Goldberg completed his PhD and post-doctoral training at MIT under the mentorship of Robert Langer and Phillip Sharp, respectively.
The company has a team of operators and advisors that include leaders in localized therapeutics, drug delivery, translational immunotherapy, surgical oncology, drug development, and immune-engineering: Charles (“Chuck”) Carignan, MD (former Chief Medical Officer of Boston Scientific), Robert Langer, ScD (founder of Moderna), Elizabeth Jaffee, MD (Past-President of the American Association for Cancer Research), Timothy Eberlein, MD (Past-President of the Society of Surgical Oncology), Francis Cuss, MD (former Chief Scientific Officer of Bristol Myers Squibb), and Darrell Irvine, PhD (HHMI Investigator).
FinSMEs
17/10/2022